SLC5A2 and type 2 diabetes mellitus: Triple therapy comprising an SGLT-2 inhibitor, a DPP-4 inhibitor, and metformin in managing T2DM has demonstrated notable enhancements in blood glucose regulation, body weight management, and blood pressure compared to dual therapy.